Qualified Person IMP Pre-Course Session

Qualified Person IMP Pre-Course Session

Munich, Germany

Seminar Nr. 20899

 

Unser Seminarservice

Kosten

ECA-Member*: EUR 990,--
Regular Fee*: EUR 1190,--
EU/GMP Inspectorates*: EUR 595,--
QP Member Discount*: EUR 990,--

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

Zur Anmeldung
* auch unkompliziert per Kreditkarte bezahlbar American Express Visa Mastercard

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de

Sprecher

Dr Susanne Ding Boehringer Ingelheim, Germany
Patryk Jegorow, Takeda, Ireland
Sue Mann, Sue Mann Consultancy, U.K.

Zielsetzung

This pre-course session provides a detailed overview of the basic and specific characteristics in IMP manufacturing a QP must know to certify IMP batches for the release for clinical trials.

Hintergrund

The manufacture of investigational medicinal products (IMPs), including labelling, packaging, testing and certification, is carried out in accordance with the applicable GMP regulations. However, this is not a routine process, since, among other things, manufacturing and packaging procedures might be different for each and every clinical trial. The Qualified Person (QP) must therefore consider these particularities and the GMP/GCP interface.

Zielgruppe

New colleagues becoming IMP QPs, QPs looking for continuous training and personnel of CROs and “non-commercial” IMP organisations.

Programm

General Introduction
  • Different clinical phases I to IV, focus on patient safety
  • Undefined processes (manufacture, fit for purpose control strategy, etc.)
  • Why use risk assessments & how to apply – vital core of a IMP quality system
  • Diversity: IMP manufacturers, start-ups, academia…
Specific Legal Requirements for IMPs
  • Clinical Trial Regulation EU No. 536/2014 and the “old” Annex 13 and Directives 2001/20/EC and 2003/94/C
  • The “new” ATMP Regulation
GMP meets Clinical Trials – Differences between IMPs and Commercial Products
  • Packaging & labeling
  • Randomization
  • Blinding / placebos
  • Comparators
  • NIMPs / AMPs
  • Where to apply validation activities
  • The Product Specification File (PSF)
  • 3rd country manufacture of IMPs: import and the QP Declaration
Registration
  • IMPD, CTA, IND etc.
  • Regulatory compliance and the two-step release procedure
GMP/ GDP/ GCP Interface
  • Interaction with clinical sites
  • Distribution
  • IRT

Zurück

GMP Seminare nach Thema